Search results for " liver metastasis"

showing 3 items of 3 documents

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Co-expression of CD133+/CD44+in human colon cancer and liver metastasis

2013

Although relatively good therapeutic results are achieved in non-advanced cancer, the prognosis of the advanced colon cancer still remains poor, dependent on local or distant recurrence of the disease. One of the factors responsible for recurrence is supposed to be cancer stem cells (CSCs) or tumor-initiating cells, which are a population of cancer cells with ability to perpetuate themselves through self-renewal and to generate differentiated cells, thought to be responsible for tumor recurrence. This study globally approach the possible role of tissue-derived stem cells in the initiation of colon cancer and its metastatic process in the liver. Fresh surgical specimens from colon cancer, no…

MaleCA15-3PhysiologyColorectal cancerSettore MED/06 - Oncologia MedicaClinical BiochemistryMetastasisCirculating tumor cellHermes antigen EMTREE medical terms: adultAC133 Antigencell populationcancer cellclinical articleColonic NeoplasmCD133 antigen; Hermes antigen adult; aged; article; cancer cell; cancer stem cell; cancer tissue; cell clone; cell compartmentalization; cell isolation; cell population; clinical article; colon cancer; disease association; female; human; human cell; human tissue; liver metastasis; male; phenotype; priority journal; protein expression Adult; Aged; Antigens CD; Antigens CD44; Colonic Neoplasms; Female; Glycoproteins; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Tumor Markers Biological [EMTREE drug terms]biologyLiver Neoplasmsarticlecell cloneMiddle AgedImmunohistochemistryAntigens CD44Hyaluronan Receptorsfemalecolon cancerpriority journalLiver NeoplasmTumor Markers BiologicalColonic NeoplasmsPeptideNeoplastic Stem Cellscancer tissueAdultEMTREE drug terms: CD133 antigencancer stem cellphenotypeprotein expression MeSH: Adultcell isolationAntigens CDCancer stem cellBiomarkers TumormedicineHumansliver metastasihumanGlycoproteinsAgedbusiness.industryhuman celldisease associationCD44CancerCell Biologymedicine.diseasehuman tissueCancer cellImmunologybiology.proteinCancer researchcell compartmentalizationNeoplastic Stem CellGlycoproteinPeptidesbusiness
researchProduct

The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-an…

2016

Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of liver metastasis (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Materials and Methods: Data from all published studies reporting survival outcomes (RFS and/or OS) of CRC patients who received resection of CLM, stratified by KRAS and/or BRAF mutation status were collected by sear…

Settore MED/06 - Oncologia MedicaKRAS BRAF prognostic colorectal cancer liver metastasis meta-analysis
researchProduct